Cyclica, Genome Institute of Singapore sign drug discovery partnership
Canadian biotech company Cyclica has signed a multi-year and multi-project drug discovery partnership with the Genome Institute of Singapore (GIS) in oncology and related diseases. ... Read More
Gilead Sciences, Second Genome form IBD drug discovery alliance
Gilead Sciences has entered into a four-year deal worth up to $338 million with California-based clinical-stage company Second Genome to discover targets and drug candidates ... Read More
Polarisqb, Fujitsu join forces to create dengue drug discovery platform
Polarisqb has joined forces with Fujitsu to create a Dengue drug discovery platform that brings together quantum-inspired technology, hybrid quantum mechanics, machine learning, and molecular ... Read More
AbbVie, Scripps Research to collaborate on developing new therapeutics
US biopharma company AbbVie has entered into a collaboration with California-based nonprofit medical research facility Scripps Research with a goal to develop new therapies for ... Read More
GE Healthcare, ASLS form R&D partnership to advance 3D biofabrication
GE Healthcare Life Sciences has joined forces with Advanced Solutions Life Sciences (ASLS) for an R&D and distribution partnership with a goal to create new ... Read More
AstraZeneca taps into Gatehouse Bio’s sRNAlytics AI platform for drug discovery
US biodata company Gatehouse Bio is joining forces with pharma giant AstraZeneca to accelerate the discovery of new drugs for respiratory and cardiovascular diseases using ... Read More
Chinese biopharma company Akeso raises $150m for antibody drug discovery
Akeso, a Chinese biopharma company engaged in antibody drug discovery and development in oncology and immunology therapeutic areas, has raised nearly $150 million through a ... Read More
Yuhan Pharmaceuticals to use Cyclica’s AI-driven drug discovery platform
Yuhan Pharmaceuticals has entered into a collaboration with Canadian biotechnology company Cyclica to use the latter's artificial intelligence (AI) driven integrated drug discovery platform in ... Read More
Dicerna, Roche strike $1.67bn deal for hepatitis B virus therapies
Dicerna Pharmaceuticals has secured a research collaboration and licensing deal worth up to $1.67 billion with Roche to develop new drugs for chronic hepatitis B ... Read More
Pepticom secures investment for AI-driven peptide drug discovery
Israel-based Pepticom, which is engaged in using artificial intelligence (AI) for peptide drug discovery, has raised $5 million in a Series A funding round from the ... Read More